Trials / Terminated
TerminatedNCT00366080
Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy
An Open Label, Dose Escalation Study With A Double Blind Randomised Placebo Controlled Withdrawal To Examine The Effects Of The Histamine H3 Antagonist GSK189254 In Patients With Narcolepsy.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effectiveness and safety of the drug GSK189254 in treating patients with narcolepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK189254 |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2006-08-18
- Last updated
- 2017-03-10
Locations
14 sites across 6 countries: Austria, Finland, Germany, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00366080. Inclusion in this directory is not an endorsement.